These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 32562513)

  • 1. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study.
    Białek Ł; Czerwińska K; Fus Ł; Krajewski W; Sadowska A; Radziszewski P; Dobruch J; Kryst P; Poletajew S
    Cancer Biomark; 2021; 30(2):139-143. PubMed ID: 32924986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER.
    Dudderidge T; Stockley J; Nabi G; Mom J; Umez-Eronini N; Hrouda D; Cresswell J; McCracken SRC
    Eur Urol Oncol; 2020 Feb; 3(1):42-46. PubMed ID: 31307961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
    Kelly JD; Dudderidge TJ; Wollenschlaeger A; Okoturo O; Burling K; Tulloch F; Halsall I; Prevost T; Prevost AT; Vasconcelos JC; Robson W; Leung HY; Vasdev N; Pickard RS; Williams GH; Stoeber K
    PLoS One; 2012; 7(7):e40305. PubMed ID: 22792272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
    Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
    BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study.
    Roupret M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Sylvester R; Longo F; Montanari E; Palou J
    J Urol; 2020 Oct; 204(4):685-690. PubMed ID: 32314931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does urinary cytology have a role in haematuria investigations?
    Tan WS; Sarpong R; Khetrapal P; Rodney S; Mostafid H; Cresswell J; Watson D; Rane A; Hicks J; Hellawell G; Davies M; Srirangam SJ; Dawson L; Payne D; Williams N; Brew-Graves C; Feber A; Kelly JD;
    BJU Int; 2019 Jan; 123(1):74-81. PubMed ID: 30003675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.
    Brisuda A; Háček J; Čechová M; Škapa P; Babjuk M
    Cytopathology; 2019 Sep; 30(5):510-518. PubMed ID: 30943322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
    Konety BR; Metro MJ; Melham MF; Salup RR
    Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
    Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
    Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
    Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urinary cytology in cases of bladder cancer: a critical evaluation].
    Rathert P
    Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.